Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 29;26(11):5241.
doi: 10.3390/ijms26115241.

Recent Advances in Genetics of Moyamoya Disease: Insights into the Different Pathogenic Pathways

Affiliations
Review

Recent Advances in Genetics of Moyamoya Disease: Insights into the Different Pathogenic Pathways

Guangsong Han et al. Int J Mol Sci. .

Abstract

Moyamoya disease (MMD) is a rare yet clinically significant cerebrovascular disorder characterized by progressive stenosis of the distal internal carotid artery and/or its principal branches, accompanied by the development of characteristic collateral vessel networks. This disease demonstrates a complex multifactorial etiology with strong genetic determinants, as evidenced by its distinct geographical distribution patterns and familial clustering. Recent genetic researches have identified multiple pathogenic mutations contributing to MMD development through three principal mechanisms: progressive vascular stenosis, abnormal angiogenesis, and dysregulated inflammatory responses. Furthermore, moyamoya syndrome frequently occurs as a secondary vascular complication in various monogenic disorders. This review provides a comprehensive analysis of recent genetic advances in MMD in view of diverse pathogenic pathways, offering valuable perspectives on the molecular mechanisms underlying disease development and potential therapeutic targets.

Keywords: genetics; moyamoya disease; moyamoya syndrome; pathogenic; pathways.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Integrated pathophysiological network of Moyamoya disease: Molecular crosstalk across angiogenic dysregulation, epigenetic modulators, and metabolic-immune axis. Italicized text indicates relevant genes; PDGF: platelet-derived growth factor; OGFR: opioid growth factor receptor; CCL2: cell chemokine ligand 2; Ang-1/2: angiopoietin-1/2; Cav-1: caveolin-1; ICAM1: intercellular adhesion molecule 1; TGF-β: transforming growth factor β; bFGF: basic fibroblast growth factor; VEGF: vascular endothelial growth factor; NF-κB: nuclear factor κ-B; NFAT: nuclear factor of activated T-cells; TNF-α: tumor necrosis factor-α; IFN-γ: interferon-γ; NO-sGC-cGMP: nitric oxide-soluble guanylyl cyclase-cyclic guanosine monophosphate; MMPs: matrix metalloproteinases; TIMPs: tissue inhibitors of metalloproteinases.

Similar articles

References

    1. Ihara M., Yamamoto Y., Hattori Y., Liu W., Kobayashi H., Ishiyama H., Yoshimoto T., Miyawaki S., Clausen T., Bang O.Y., et al. Moyamoya disease: Diagnosis and interventions. Lancet Neurol. 2022;21:747–758. doi: 10.1016/S1474-4422(22)00165-X. - DOI - PubMed
    1. He S., Zhou Z., Cheng M.Y., Hao X., Chiang T., Wang Y., Zhang J., Wang X., Ye X., Wang R., et al. Advances in moyamoya disease: Pathogenesis, diagnosis, and therapeutic interventions. MedComm. 2025;6:e70054. doi: 10.1002/mco2.70054. - DOI - PMC - PubMed
    1. Scott R.M., Smith E.R. Moyamoya disease and moyamoya syndrome. N. Engl. J. Med. 2009;360:1226–1237. doi: 10.1056/NEJMra0804622. - DOI - PubMed
    1. Mertens R., Graupera M., Gerhardt H., Bersano A., Tournier-Lasserve E., Mensah M.A., Mundlos S., Vajkoczy P. The Genetic Basis of Moyamoya Disease. Transl. Stroke Res. 2022;13:25–45. doi: 10.1007/s12975-021-00940-2. - DOI - PMC - PubMed
    1. Chen T., Wei W., Yu J., Xu S., Zhang J., Li X., Chen J. The Progression of Pathophysiology of Moyamoya Disease. Neurosurgery. 2023;93:502–509. doi: 10.1227/neu.0000000000002455. - DOI - PubMed

LinkOut - more resources